IGF2BP3 and acute myeloid leukemia: As IGF2BP3 is highly expressed in patients with AML and is negatively correlated with patient survival (P < 0.001, Fig. 4B), compared to HNRNPA2B1 (P = 0.288, Fig. 4C) and YTHDF3 (P = 0.032, Fig. 4D).